Knight Therapeutics (KHTRF) Rating Reiterated by Paradigm Capital

Paradigm Capital restated their hold rating on shares of Knight Therapeutics (OTCMKTS:KHTRF) in a research report sent to investors on Friday, April 5th, TipRanks reports.

Separately, Raymond James restated a buy rating on shares of Knight Therapeutics in a report on Wednesday, January 16th.

KHTRF remained flat at $$5.57 during midday trading on Friday. Knight Therapeutics has a 1-year low of $5.45 and a 1-year high of $6.72.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Recommended Story: Why are gap-down stocks important?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.